Premium Phosphosite-Specific 7TM Antibodies
Novel Tools for Your GPCR Research
Select Your Country of Delivery below

Immuno-Grade Somatostatin Receptor 2 Antibody

Close filters
No results were found for the filter!
Citations
KO-Validated
Immunohistochemical identification of Somatostatin Receptor 2 in human neuroendocrine tumor tissue.
SST2 (IHC-grade), Somatostatin Receptor 2 Antibody
The SST2 receptor antibody is directed against the distal end of the carboxyl-terminal tail of mouse, rat and human Somatostatin Receptor 2. It detects selectively the canonical form of SST2 (also referred to as SST2A) and not the...
$ 400.00 *
Details
NEW
Immunohistochemical identification of Somatostatin Receptor 2 in human neuroendocrine tumor tissue
SST2 (GP-IHC-grade), Somatostatin Receptor 2...
The SST2 receptor antibody is directed against the distal end of the carboxyl-terminal tail of human Somatostatin Receptor 2. It detects selectively the canonical form of SST2 (also referred to as SST2A) and not the putative splice...
$ 400.00 *
Details

The somatostatin receptor 2 (SST2) is the primary target for octreotide (Sandostatin) and lanreotide (Somatuline) which are the first line medical treatment for growth hormone (GH)-producing adenomas (acromegaly) and gastrointestinal neuroendocrine tumors. SST2 is a prototypical GPCR for the development of peptide-based radiopharmaceuticals, which are used for imaging of human tumors as well as for peptide receptor radionuclide therapy (PRRT). The SST2 receptor is abundantly localized at the plasma membrane of a variety of normal tissues including anterior pituitary, pancreatic islets, enterochromaffine cells throughout the gut, enteric ganglion cells, cerebral cortex and immune cells. SST2 is highly expressed in many neuroendocrine tumors including pituitary adenoma, carcinoid and pheochromocytoma. SST2 immunohistochemistry predicts response to octreotide.

The somatostatin receptor 2 (SST2) is the primary target for octreotide (Sandostatin) and lanreotide (Somatuline) which are the first line medical treatment for growth hormone (GH)-producing... read more »
Close window
Immuno-Grade Somatostatin Receptor 2 Antibody

The somatostatin receptor 2 (SST2) is the primary target for octreotide (Sandostatin) and lanreotide (Somatuline) which are the first line medical treatment for growth hormone (GH)-producing adenomas (acromegaly) and gastrointestinal neuroendocrine tumors. SST2 is a prototypical GPCR for the development of peptide-based radiopharmaceuticals, which are used for imaging of human tumors as well as for peptide receptor radionuclide therapy (PRRT). The SST2 receptor is abundantly localized at the plasma membrane of a variety of normal tissues including anterior pituitary, pancreatic islets, enterochromaffine cells throughout the gut, enteric ganglion cells, cerebral cortex and immune cells. SST2 is highly expressed in many neuroendocrine tumors including pituitary adenoma, carcinoid and pheochromocytoma. SST2 immunohistochemistry predicts response to octreotide.

Recently viewed